Prevalence, Mechanisms, and Outcome of Tricuspid Valve Regurgitation in the Elderly
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Tricuspid Regurgitation
- Sponsor
- Al-Azhar University
- Enrollment
- 700
- Locations
- 1
- Primary Endpoint
- Prevalence of tricuspid valve regurgitation in the elderly
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
Tricuspid regurgitation (TR) is the second most common VHD after MR. Its prevalence also increases with age, with an estimated incidence of up to 6% in elderly population. When adjusted to age (among other confounders), survival is worse for patients with moderate and severe TR. We aim to explore the prevalence, mechanisms, and clinical implications of tricuspid valve regurgitation in elderly subjects screened at a tertiary center in Cairo, Egypt.
Investigators
Mohammad Abdelghani
Lecturer of Cardiology - Cardiology Consultant
Al-Azhar University
Eligibility Criteria
Inclusion Criteria
- •All comer patients ≥60-year-old presenting to the echocardiography clinic
Exclusion Criteria
- •Poor acoustic window.
Outcomes
Primary Outcomes
Prevalence of tricuspid valve regurgitation in the elderly
Time Frame: Baseline (at enrolment)
Prevalence of mild, moderate, and severe TR in enrolled patients
All-cause mortality
Time Frame: At 6 months
Incidence of death from any cause
Rehospitalization for congestive heart failure
Time Frame: At 6 months
Incidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization.
Cardiovascular mortality
Time Frame: At 6 months
Incidence of cardiovascular death, defined as death attributable to myocardial ischemia and infarction, heart failure, cardiac arrest because of other or unknown cause, or cerebrovascular accident.
Secondary Outcomes
- Classification of tricuspid valve regurgitation in the elderly(Baseline)
- Change in New York Heart Association (NYHA) functional class(At 6, 12 and 60 months)
- All-cause mortality(At 12 and 60 months)
- Cardiovascular mortality(At 12 and 60 months)
- Rehospitalization for congestive heart failure(At 12 and 60 months)